ProclaRx recently appointed Doug Martin as its new COO, assigning him strategic planning, compliance and coordination of R&D duties.
Martin will report directly to ProclaRx Chairman of the Board Nick Henderson.
"We are extremely pleased to have someone with Doug's extensive background and experience join ProclaRx as we continue to accelerate the development of our anti-biofilm technology," Henderson said. "His intimate knowledge of how complex, multi-billion dollar corporations function gives Doug the skill portfolio needed to drive our company forward."
Prior to joining ProclaRx, Martin was director of corporate strategy with Applied Bio Ventures.
"I am honored to join the ProclaRx team of experienced scientists, researchers, and drug commercialization experts whose singular vision is to efficiently and effectively help children and adults with chronic and intractable infections," Martin said. "The ProclaRx anti-biofilm technology represents a profound, new approach to addressing bacterial infections, which includes the reduction of antibiotic use while clearing infections. To prolong the useful life of antibiotics, the medical community needs a disruptive approach to the attack on infections.”